Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

Executive Summary

Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004

You may also be interested in...



Elan Meltdown May End R&D Joint Ventures As Funding Vehicle For Biotech

The Elan market meltdown is likely to shut off the joint venture route as one avenue for struggling biotech companies to obtain capital

Teva Oral Copaxone Could Be Studied At Higher Dose After Interim Analysis

Teva is considering conducting a Phase III trial evaluating a higher dose of oral Copaxone (glatiramer acetate) after an interim analysis of Teva's Phase III study of the oral formulation suggested that the trial will not meet its endpoints.

R.W. Johnson Mylinax

FDA cancels Jan. 29 meeting of the Peripheral & Central Nervous System Drugs Advisory Committee. The committee was scheduled to review Mylinax (cladribine) for treatment of multiple sclerosis

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel